Global Viral And Non Viral Vector Manufacturing Market Report Forecast 2024 - 2033
6 Aug, 2024
The viral and non-viral vector manufacturing market witnessed substantial growth, escalating from $7.22 billion in 2023 to $8.62 billion in 2024, reflecting a 19.5% CAGR. This trend attributed to increasing genetic disorder prevalence, biotechnology advancements, gene therapy research investments, personalized medicine awareness, and regulatory backing. Forecasts suggest accelerated expansion, with the market projected to reach $17.85 billion by 2028, boasting a 20.0% CAGR. Driving forces include gene therapy demand, rare disease treatment applications, biomanufacturing infrastructure investments, and precision medicine adoption. Upcoming trends encompass next-gen viral vectors, CRISPR/Cas9 utilization, scalable manufacturing processes, non-viral vector adoption, and manufacturing technology advancements.
Major Driver In The Viral And Non Viral Vector Manufacturing Market
The viral and non-viral vector manufacturing markets are set to grow in response to a rising incidence of genetic disorders. Organizations like Versus Arthritis report increasing numbers of individuals affected by disorders such as arthritis, while the International Diabetes Federation predicts a significant rise in diabetes cases worldwide by 2045, driving demand for vector manufacturing solutions.
Request A Free Sample Of The Global Viral And Non Viral Vector Manufacturing Market ReportViral And Non Viral Vector Manufacturing Market Competitive Landscape
Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.
Key Viral And Non Viral Vector Manufacturing Market Trend
Technological advancements are shaping the viral and non-viral vector manufacturing markets, with major companies developing cutting-edge solutions to sustain their market leadership. For instance, in August 2022, Merck KGaA, a Germany-based science and technology company, introduced the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. This platform revolutionizes viral vector manufacturing by offering a comprehensive package that includes AAV, Lentiviral, CDMO, CTO, and process development services. It enables biopharmaceutical companies to streamline process development, accelerate clinical manufacturing timelines, and reduce costs.
Purchase The Global Viral And Non Viral Vector Manufacturing Market Report Directly And Get A Swift Delivery
Viral And Non Viral Vector Manufacturing Market Segmentation
The viral and non-viral vector manufacturing market covered in this report is segmented –
1) By Vector Type: Viral Vector, Non-Viral Vector
2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications
By Geography: The regions covered in the viral and non-viral vector manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the viral and non-viral vector manufacturing market in 2023.
The Viral And Non-Viral Vector Manufacturing Global Market Report 2024 furnishes information about the global viral and non-viral vector manufacturing market, encompassing details like market size, projections for growth, segmentation across various sectors and regions, and an overview of competitors, including their revenues, profiles, and market shares. Furthermore, the report pinpoints potential opportunities and strategic directions derived from market trends and the strategies adopted by key competitors. The report also offers an assessment of how the COVID-19 pandemic, the Russia-Ukraine conflict, and increasing inflation have affected both global and regional markets, furnishing valuable strategic insights for businesses.